PolyPid (PYPD) to Release Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect PolyPid to post earnings of ($0.34) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.17.

PolyPid Stock Up 1.3%

Shares of PolyPid stock opened at $4.58 on Tuesday. PolyPid has a 52 week low of $2.30 and a 52 week high of $5.12. The stock’s 50-day simple moving average is $4.32 and its 200-day simple moving average is $3.79. The company has a market capitalization of $72.82 million, a price-to-earnings ratio of -1.54 and a beta of 1.52.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Finally, Roth Mkm reduced their price target on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.25.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. HighTower Advisors LLC bought a new position in PolyPid Ltd. (NASDAQ:PYPD) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,244 shares of the company’s stock, valued at approximately $44,000. HighTower Advisors LLC owned 0.06% of PolyPid as of its most recent SEC filing. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.